Altimmune, Inc. ALT
NASDAQ · United States · Health Technology
$2.74-0.02 (-0.91%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinic
Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.
On August 12, Altimmune (NASDAQ:ALT) reported second quarter results that read less like a routine earnings update and more like a status check on three separate diseases at the same time. The clinical-stage biopharmaceutical company disclosed a newly launched global Phase 3 trial in MASH, positive Phase 2 data in alcohol use disorder, and completed […]
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clin
Altimmune reports positive Phase 2 AUD data and rapid progress in its MASH Phase 3 trial, backed by $519 million in cash.
Moby summary of Altimmune, Inc.'s Q2 2026 earnings call
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced fina
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.